BR112022007158A2 - Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico - Google Patents

Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico

Info

Publication number
BR112022007158A2
BR112022007158A2 BR112022007158A BR112022007158A BR112022007158A2 BR 112022007158 A2 BR112022007158 A2 BR 112022007158A2 BR 112022007158 A BR112022007158 A BR 112022007158A BR 112022007158 A BR112022007158 A BR 112022007158A BR 112022007158 A2 BR112022007158 A2 BR 112022007158A2
Authority
BR
Brazil
Prior art keywords
combination
immunological checkpoint
immunomodulatory agents
checkpoint inhibitors
patient
Prior art date
Application number
BR112022007158A
Other languages
English (en)
Inventor
C Losey Heather
Lopes Jared
J Winquist Raymond
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of BR112022007158A2 publication Critical patent/BR112022007158A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

AGENTES IMUNOMODULATÓRIOS DE IL-2 EM COMBINAÇÃO COM INIBIDORES DO PONTO DE VERIFICAÇÃO IMUNOLÓGICO. A invenção fornece composições e métodos para tratar câncer em um paciente com uma terapia de combinação compreendendo uma proteína de fusão de SEQ ID NO: 1 em combinação com um inibidor do ponto de verificação imunológico. Preferencialmente, o paciente não conseguiu alcançar resposta completa ou parcial com tratamento prévio ou em andamento com um inibidor do ponto de verificação imunológico.
BR112022007158A 2019-10-18 2020-10-16 Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico BR112022007158A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916936P 2019-10-18 2019-10-18
PCT/IB2020/000860 WO2021074689A1 (en) 2019-10-18 2020-10-16 Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
BR112022007158A2 true BR112022007158A2 (pt) 2022-07-05

Family

ID=73695073

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007158A BR112022007158A2 (pt) 2019-10-18 2020-10-16 Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico

Country Status (12)

Country Link
US (2) US11248050B2 (pt)
EP (1) EP4045077A1 (pt)
JP (1) JP2022553234A (pt)
KR (1) KR20220084066A (pt)
CN (1) CN114555110A (pt)
AU (1) AU2020367403A1 (pt)
BR (1) BR112022007158A2 (pt)
CA (1) CA3157229A1 (pt)
IL (1) IL292219A (pt)
MX (1) MX2022004577A (pt)
WO (1) WO2021074689A1 (pt)
ZA (1) ZA202203567B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916241A (zh) * 2020-04-15 2023-04-04 奥克梅斯制药爱尔兰有限公司 与血管生成抑制剂组合的免疫刺激剂
KR20230016178A (ko) 2020-04-15 2023-02-01 엘커메스 파마 아일랜드 리미티드 혈관신생 억제제와 조합된 면역자극제
US20210371486A1 (en) * 2020-05-11 2021-12-02 Alkermes Pharma Ireland Limited Il-2 fusion polypeptide compositions and methods of making and using the same
AU2021269585A1 (en) * 2020-05-11 2022-12-15 Alkermes Pharma Ireland Limited IL-2 fusion polypeptide compositions and methods of making and using the same
WO2022256538A1 (en) * 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
WO2023122573A1 (en) * 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CA2869674A1 (en) 2012-06-08 2013-12-12 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
EP4032540A1 (en) 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
MA40721A (fr) * 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
MX2020004914A (es) * 2017-11-13 2020-10-28 Bioxcel Therapeutics Inc Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario.
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy

Also Published As

Publication number Publication date
US20220227868A1 (en) 2022-07-21
US20210163596A1 (en) 2021-06-03
KR20220084066A (ko) 2022-06-21
CN114555110A (zh) 2022-05-27
JP2022553234A (ja) 2022-12-22
IL292219A (en) 2022-06-01
ZA202203567B (en) 2022-11-30
AU2020367403A1 (en) 2022-04-14
US11945870B2 (en) 2024-04-02
US11248050B2 (en) 2022-02-15
MX2022004577A (es) 2022-05-10
CA3157229A1 (en) 2021-04-22
WO2021074689A1 (en) 2021-04-22
EP4045077A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MY167232A (en) Polypeptides binding to human complement c5
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MD3768284T2 (ro) Compoziţii de entrecoccus flagellin pentru utilizare în terapie
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
EA201890728A2 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
MX2022001004A (es) Inhibidores de enzimas.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
CL2019000846A1 (es) Proteína terapéutica.
PH12021550122A1 (en) Solubilized apyrases, methods and use
CO2022000270A2 (es) Inhibidores de enzimas
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
EA202092530A1 (ru) Способы облегчения старческой астении и старения
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
MX2022000847A (es) Dosificacion para la prevencion o tratamiento de la enfermedad de injerto contra huesped (gvhd) con proteinas de fusion il-22 fc.
BR112022020846A2 (pt) Agentes imunoestimuladores em combinação com inibidores de angiogênese
BR112022020871A2 (pt) Agentes imunoestimuladores em combinação com inibidores da angiogênese
BR112022006267A2 (pt) Método para tratar hiv com cabotegravir e rilpivirina